JPRN-UMIN000015867已完成未知
Effect of GLP-1 receptor agonist in combination with insulin on abdominal fat in patients with type 2 diabetes trial - GLP-1 receptor agonist and abodominal fat in diabetes
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
iraglutide treatment significantly reduced visceral fat area (VFA) at 24 weeks; whereas, subcutaneous fat are (SFA) was unchanged. albuminuria, liver attenuation index, and CRP levels were significantly reduced by liraglutide at 24 weeks and there was no difference in skeletal muscle index between the two groups.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Type 1 diabetes Patients with allergy to incretin mimetics Patients with interstitial pneumonia Patints with liver chirrosis or renal failure Patients who had experienced acute coronary syndrome or stroke or acute pancreatitis within 3 months prior to enrollment Patients with malignant neoplasms Patients who are alread treated with DPP4 inhibitors and/or GLP-1 receptor agonists. Patients whose dosage of insulin has been changed by > 20 % within 3 months prior to enrollment
研究者
相似试验
Unknown
3 期
Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in HumansObesityType 2 Diabetes MellitusNCT02718950University of Campinas, Brazil20
招募中
不适用
Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 YearsDiabetesNCT05990374Nanjing First Hospital, Nanjing Medical University100
Unknown
不适用
Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory StatusObesityNCT02118376Shanghai 10th People's Hospital20
已完成
不适用
Gastric Volume in Patients on GLP-1 MedicationsDiabetesNCT05903482Children's Hospital of Philadelphia70
撤回
4 期
Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial FatMonoclonal GammopathiesOverweightObesityNCT02920190University of Miami